Copyright © 2019 EnBiotix, Inc.. All Rights Reserved

Address a critical unmet need in ventilated pneumonias:

US VAP Cases/Year
% of All ICU Antibiotics for VAP
Healthcare Costs Per Case ($)
% Mortality Rate (Low Estimate)
% Reinfection Rate

Anticipated as first approved inhaled antibiotic for ventilated pneumonias:

  • Effective against hospital-acquired pneumonia (HAP) and resistant isolates
  • Reduces/replaces IV antibiotics as standard-of-care
  • Reduces systemic side effects of IV antibiotics